Medicaps Limited

BSE: 523144
Medicaps Limited - pharma in Indore, Madhya Pradesh, India. FY 2026 financials and compliance.
CIN L70100MP1983PLC002231 Incorporated 06 August 1983 ROC Gwalior HQ Indore, Madhya Pradesh, India
Active Listed - BSE: 523144 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹12.45 Cr
▼ 51.14% YoY
EBITDA · FY 2026
-₹1.2 Cr
▼ 233.3% YoY
Net profit · FY 2026
-₹3.04 Cr
▼ 431.96% YoY
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹12.47 Cr
Issued & subscribed
Open charges
₹20 Lakh
Satisfied ₹2.22 Cr
Company age
43 yrs
Est. 1983
Employees · EPFO
2
Latest available

About Medicaps Limited

Data last updated: 11 January 2026

Medicaps Limited is a public limited company based in Indore, Madhya Pradesh, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 06 August 1983, the company has been in operation for over 43 years.

Registered with ROC Gwalior under CIN L70100MP1983PLC002231. Listed on BSE: 523144.

Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.47 Cr. Formerly known as Medicaps Pvt Limited. It is led by directors including Ashok Agrawal Omprakash and Gajendra Singh.

Last AGM: 18 September 2025. Financial statements filed for year ended 31 March 2025. Office: Indore, Madhya Pradesh.

As per the financials filed for FY 2025, the company reported a revenue of ₹28.21 Cr, a growth of 1% compared to the previous year.

The company has a workforce of approximately 2 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Medi-Caps. As per MCA filings, the company has open charges of ₹20 Lakh and satisfied charges of ₹2.22 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicaps.com.

Company Details of Medicaps Limited
CIN L70100MP1983PLC002231
Registration Number 002231
Incorporation Date 06 August 1983
ROC Gwalior
Listing Status Listed (BSE: 523144)
Company Status Active
Date of Last AGM 18 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
DPIIT Recognition Recognised Startup
Key People
Alok K Garg Managing Director Ashok Agrawal Omprakash Director Gajendra Singh Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    medicaps.com
  • Social Media
    **************
  • Registered Address
    201 Pushpratna Paradise, 9/5 New Palasiya, Indore, Madhya Pradesh, India – 452001
  • Industry
    Pharma, Drug Formulation & Development
Company report
Medicaps Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Medicaps Limited report

Financials, compliance, directors, charges, ownership and filings for Medicaps Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Medicaps Limited

Medicaps Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L70100MP1983PLC002231, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L70100MP1983PLC002231 Current
U24232MP1983PLC002231 Previous
L24232MP1983PLC002231 Previous

Associated Brands with Medicaps Limited

Medicaps Limited operates one associated brand: Medi-Caps. These brands represent Medicaps Limited's diversified market presence and brand portfolio.

Brand Description Website
Medi-Caps
Manufacturer of empty gelatin capsules medicaps.com

Competitors & Alternatives of Medicaps Limited

Brands and companies operating in the same space as Medicaps Limited include Inventia Healthcare, Zim Labs, Lotus and 7 more.

Competitor Description Location Founded
Inventia Healthcare Inventia Healthcare Oral solid drug delivery systems are manufactured and developed. Mumbai, India, India 1985
Zim Labs Zim Labs Solid and semisolid dosage forms are developed and manufactured. Nagpur, India, India 1989
Lotus Lotus Contract manufacturing for oral solid formulations is offered. Taipei, Taiwan, Taiwan 1966
Contract Pharmacal Corp. Contract Pharmacal Corp. Product development, manufacturing and packaging services Hauppauge, United States, United States 1971
Adare Pharma Solutions Adare Pharma Solutions CDMO manufacturing solid drugs Lawrence Township, United States, United States 2015
Suzhou Ze Jing Biological Pharmaceutical Suzhou Ze Jing Biological Pharmaceutical Company developing small molecules & eukaryotic cell based recombinant protein drugs Suzhou, China, China 2009
Halewood Laboratories Halewood Laboratories Provides contract manufacturing services for food, pharmaceuticals, and related products globally. Ahmedabad, India, India 1984
Capsugel Capsugel Dosage forms are delivered for preclinical, clinical, and commercial supply. Morristown, United States, United States 1875
Glukem Glukem Manufactures pellets, micro-pellets, granules, and capsules for pharmaceutical and nutraceutical drugs. Hyderabad, India, India 2014
Vovantis Laboratories Vovantis Laboratories Develops and manufactures novel effervescent drug delivery systems. Vadodara, India, India 2008

Business Activity of Medicaps Limited

Medicaps Limited is engaged in the principal business activity of real estate, with detailed activities including real estate activities with own or leased property.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
L Real Estate L1 Real estate activities with own or leased property *********

Auditor Details of Medicaps Limited

Medicaps Limited is audited by Rawka & Associates (ICAI peer reviewed, certificate valid till 2029-04-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Rawka & Associates (ICAI peer reviewed, certificate valid till 2029-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Medicaps Limited

Medicaps Limited is currently managed by 9 directors, with 22 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ashok Agrawal Omprakash
Also directs: Medicaps Limited, Medgel Private Limited
Director 25 Jul 2017 8 Years 11 Months Current
Gajendra Singh
Also directs: Medicaps Limited
Director 11 Aug 2023 2 Years 10 Months Current
Dharmendra Solanki
Also directs: Medicaps Limited
Director 05 Feb 2021 5 Years 5 Months Current
Ramesh Chandra Mittal
Also directs: Trapti Investments Llp, Taurus Dwellers Llp, Saffron Realties Llp and 5 more
Director 06 Aug 1983 42 Years 11 Months Current
Kusum Mittal
Also directs: Trapti Investments Llp, Taurus Dwellers Llp, Saffron Realties Llp and 1 more
Director 04 May 1991 35 Years 2 Months Current
Alok K Garg
Also directs: Medicaps Limited, Medgel Private Limited
Managing Director 01 Apr 2007 19 Years 3 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Medicaps Limited FY 2026 filings available

Medicaps Limited reported revenue of ₹12.45 Cr (down 51.14% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹12.45 Cr ▼ 51.14%
Profit · FY 2026
-₹3.04 Cr ▼ 431.96%
EBITDA · FY 2026
-₹1.2 Cr ▼ 233.3%
Revenue₹ Cr · Consolidated0255075FY 2019: ₹54 Cr53.9FY 2019FY 2020: ₹45 Cr · -15.9% YoY45.3-15.9%FY 2020FY 2021: ₹59 Cr · +29.5% YoY58.7+29.5%FY 2021FY 2022: ₹70 Cr · +19% YoY69.9+19%FY 2022FY 2023: ₹49 Cr · -29.3% YoY49.4-29.3%FY 2023FY 2024: ₹27 Cr · -44.6% YoY27.3-44.6%FY 2024FY 2025: ₹25 Cr · -6.8% YoY25.5-6.8%FY 2025FY 2026: ₹12 Cr · -51.1% YoY12.4-51.1%FY 2026
Net Profit₹ Cr · Consolidated-10-5051015FY 2019: ₹5 Cr5.4FY 2019FY 2020: ₹6 Cr (loss) · -208.6% YoY-5.9FY 2020FY 2021: ₹11 Cr · +290.2% YoY11.1+290.2%FY 2021FY 2022: ₹10 Cr · -9.4% YoY10.1-9.4%FY 2022FY 2023: ₹2 Cr · -82.6% YoY1.8-82.6%FY 2023FY 2024: ₹2 Cr (loss) · -227.6% YoY-2.2FY 2024FY 2025: ₹1 Cr (loss) · +74.5% YoY-0.6FY 2025FY 2026: ₹3 Cr (loss) · -432% YoY-3FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0510Q1'25: ₹6 Cr6.2Q1'25Q2'25: ₹8 Cr8.3Q2'25Q3'25: ₹4 Cr4Q3'25Q4'25: ₹7 Cr7Q4'25Q1'26: ₹3 Cr · -56.6% YoY2.7-56.6%Q1'26Q2'26: ₹2 Cr · -75.7% YoY2-75.7%Q2'26Q3'26: ₹4 Cr · +6.9% YoY4.3+6.9%Q3'26Q4'26: ₹3 Cr · -50.5% YoY3.4-50.5%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹12.45 Cr ₹25.48 Cr ₹27.35 Cr ₹49.37 Cr ₹69.87 Cr ₹58.72 Cr ₹45.33 Cr ₹53.92 Cr
Other Income ₹8.21 Cr ₹2.73 Cr ₹47.5 Lakh ₹1.6 Cr ₹1.91 Cr ₹58.37 Lakh ₹59.53 Lakh ₹58.43 Lakh
Total Income ₹20.66 Cr ₹28.21 Cr ₹27.82 Cr ₹50.97 Cr ₹71.79 Cr ₹59.3 Cr ₹45.92 Cr ₹54.5 Cr
Cost of Materials Consumed ₹5.44 Cr ₹10.17 Cr ₹8.43 Cr ₹22.05 Cr ₹30.05 Cr ₹31.08 Cr ₹22.33 Cr ₹26.32 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹15.26 Lakh
Changes in Inventories ₹20.01 Lakh ₹48.17 Lakh ₹1.09 Cr ₹85.21 Lakh ₹6.43 Lakh -₹1.71 Cr ₹4.5 Cr -₹13.32 Lakh
Employee Benefit Expense ₹7.74 Cr ₹7.58 Cr ₹7.07 Cr ₹7.69 Cr ₹7.71 Cr ₹6.71 Cr ₹11.04 Cr ₹9.56 Cr
Finance Costs ₹1.3 Lakh ₹2.48 Lakh ₹0 ₹16,000 ₹2,000 ₹0 ₹1.69 Lakh ₹1.8 Lakh
Depreciation & Amortisation ₹1.81 Cr ₹1.72 Cr ₹1.69 Cr ₹1.74 Cr ₹1.81 Cr ₹1.52 Cr ₹1.83 Cr ₹1.81 Cr
Other Expenses ₹8.48 Cr ₹9.07 Cr ₹10.79 Cr ₹13.71 Cr ₹22.09 Cr ₹10.47 Cr ₹12.06 Cr ₹11.27 Cr
Total Expenses ₹23.68 Cr ₹29.05 Cr ₹29.07 Cr ₹46.05 Cr ₹61.73 Cr ₹48.06 Cr ₹51.77 Cr ₹49 Cr
Profit Before Exceptional Items & Tax -₹3.02 Cr -₹84.11 Lakh -₹1.25 Cr ₹4.92 Cr ₹10.06 Cr ₹11.24 Cr -₹5.84 Cr ₹5.5 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹3.02 Cr -₹84.11 Lakh -₹1.25 Cr ₹4.92 Cr ₹10.06 Cr ₹11.24 Cr -₹5.84 Cr ₹5.5 Cr
Total Tax Expense ₹1.41 Lakh -₹27.01 Lakh ₹99.47 Lakh ₹3.05 Cr ₹1.44 Lakh -₹51,000 ₹84,000 ₹11.65 Lakh
Net Profit -₹3.04 Cr -₹57.1 Lakh -₹2.24 Cr ₹1.76 Cr ₹10.08 Cr ₹11.13 Cr -₹5.85 Cr ₹5.39 Cr
  attributable to Owners -₹3.04 Cr -₹57.1 Lakh -₹2.24 Cr ₹1.76 Cr ₹10.08 Cr ₹11.13 Cr ₹0 ₹0
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹6.63 Cr ₹86.43 Lakh ₹4.65 Cr ₹55.95 Lakh ₹1.46 Cr ₹2.63 Cr ₹1.2 Cr ₹0
Total Comprehensive Income -₹9.66 Cr ₹29.33 Lakh ₹2.41 Cr ₹2.32 Cr ₹11.54 Cr ₹13.76 Cr -₹4.65 Cr ₹5.39 Cr
EBITDA (computed) -₹1.2 Cr ₹90.19 Lakh ₹44.05 Lakh ₹6.67 Cr ₹11.87 Cr ₹12.76 Cr -₹4 Cr ₹7.33 Cr
Basic EPS ₹-2.44 ₹-0.46 ₹-1.80 ₹1.50 ₹8.05 ₹11.13 ₹-3.73 ₹4.32
Diluted EPS ₹-2.44 ₹-0.46 ₹-1.80 ₹1.50 ₹8.05 ₹11.13 ₹-3.73 ₹4.32
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹115.46 Cr ₹125.42 Cr ₹127.28 Cr ₹125.99 Cr ₹130.35 Cr ₹114.82 Cr ₹95.21 Cr ₹106.61 Cr
Non-current Assets ₹68.44 Cr ₹71.99 Cr ₹67.27 Cr ₹65.78 Cr ₹63.66 Cr ₹62.15 Cr ₹62.08 Cr ₹64.61 Cr
Current Assets ₹47.02 Cr ₹53.44 Cr ₹60.01 Cr ₹60.2 Cr ₹66.69 Cr ₹52.67 Cr ₹33.13 Cr ₹42 Cr
Property, Plant & Equipment ₹27.07 Cr ₹27.96 Cr ₹29.43 Cr ₹30.77 Cr ₹31.17 Cr ₹29.98 Cr ₹58.26 Cr ₹58.72 Cr
Inventories ₹2.94 Cr ₹3.2 Cr ₹5.74 Cr ₹7.07 Cr ₹11.85 Cr ₹6.71 Cr ₹5.45 Cr ₹10.94 Cr
Trade Receivables ₹6.92 Cr ₹8.79 Cr ₹10.82 Cr ₹8.46 Cr ₹10.07 Cr ₹6.39 Cr ₹4.41 Cr ₹12.85 Cr
Cash & Equivalents ₹50.31 Lakh ₹41.2 Lakh ₹32.14 Lakh ₹1.11 Cr ₹28,000 ₹22,000 ₹1.25 Cr ₹2.48 Cr
Equity (Net Worth) ₹111.61 Cr ₹121.28 Cr ₹120.98 Cr ₹118.57 Cr ₹116.26 Cr ₹104.71 Cr ₹90.95 Cr ₹95.6 Cr
Equity Share Capital ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh
Borrowings (Current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹5.8 Lakh
Total Debt (computed) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹12.15 Lakh
Current Liabilities ₹2.71 Cr ₹3.1 Cr ₹5.26 Cr ₹6.39 Cr ₹13.2 Cr ₹9.27 Cr ₹3.37 Cr ₹9.14 Cr
Total Liabilities ₹3.85 Cr ₹4.15 Cr ₹6.3 Cr ₹7.42 Cr ₹14.09 Cr ₹10.11 Cr ₹4.26 Cr ₹11.01 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹7.02 Cr ₹5.07 Cr ₹6.94 Cr -₹6.08 Cr ₹7.02 Cr
Investing Cash Flow ₹7.11 Cr -₹4.98 Cr -₹7.73 Cr -₹2.56 Cr -₹4.08 Cr
Financing Cash Flow ₹0 ₹0 ₹0 ₹0 ₹0
Capital Expenditure ₹84.64 Lakh ₹32.59 Lakh ₹34.58 Lakh ₹1.16 Cr ₹2.79 Cr
Free Cash Flow (computed) -₹7.87 Cr ₹4.74 Cr ₹6.59 Cr -₹7.24 Cr ₹4.23 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash ₹9.11 Lakh ₹9.06 Lakh -₹79.21 Lakh -₹8.64 Cr ₹2.95 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹3.45 Cr ₹4.3 Cr ₹2.01 Cr ₹2.69 Cr ₹6.96 Cr ₹4.02 Cr ₹8.3 Cr ₹6.19 Cr
Other Income ₹5.59 Cr ₹75.89 Lakh ₹1.53 Cr ₹33.49 Lakh ₹2.14 Cr ₹15.9 Lakh ₹28.62 Lakh ₹14.59 Lakh
Total Income ₹9.04 Cr ₹5.06 Cr ₹3.54 Cr ₹3.02 Cr ₹9.1 Cr ₹4.18 Cr ₹8.58 Cr ₹6.34 Cr
Cost of Materials Consumed ₹1.18 Cr ₹1.29 Cr ₹1.28 Cr ₹1.69 Cr ₹2.72 Cr ₹1.39 Cr ₹2.15 Cr ₹3.91 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹35.72 Lakh ₹61.54 Lakh -₹66.9 Lakh -₹10.35 Lakh ₹5.36 Lakh ₹49.38 Lakh ₹1.78 Cr -₹1.84 Cr
Employee Benefit Expense ₹2.17 Cr ₹1.86 Cr ₹1.85 Cr ₹1.86 Cr ₹2.2 Cr ₹1.79 Cr ₹1.88 Cr ₹1.72 Cr
Finance Costs ₹0 ₹0 ₹0 ₹1.3 Lakh ₹2.48 Lakh ₹0 ₹0 ₹0
Depreciation & Amortisation ₹49.78 Lakh ₹43.68 Lakh ₹43.68 Lakh ₹43.68 Lakh ₹44.12 Lakh ₹42.57 Lakh ₹42.57 Lakh ₹42.57 Lakh
Other Expenses ₹1.8 Cr ₹1.6 Cr ₹2.46 Cr ₹2.62 Cr ₹2.21 Cr ₹2.13 Cr ₹2.03 Cr ₹2.69 Cr
Total Expenses ₹6.01 Cr ₹5.8 Cr ₹5.36 Cr ₹6.51 Cr ₹7.65 Cr ₹6.23 Cr ₹8.27 Cr ₹6.9 Cr
Profit Before Exceptional Items & Tax ₹3.03 Cr -₹73.73 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.45 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3.03 Cr -₹73.73 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.45 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
Total Tax Expense -₹1.44 Lakh ₹2.85 Lakh ₹0 ₹0 -₹27.01 Lakh ₹0 ₹0 ₹0
Net Profit ₹3.04 Cr -₹76.58 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.72 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
  attributable to Owners ₹3.04 Cr -₹76.58 Lakh -₹1.82 Cr -₹3.49 Cr ₹1.72 Cr -₹2.05 Cr ₹31.23 Lakh -₹55.65 Lakh
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹7.88 Cr ₹60.14 Lakh -₹87.61 Lakh ₹1.52 Cr -₹1.6 Cr -₹52.61 Lakh ₹1.39 Cr ₹1.6 Cr
Total Comprehensive Income -₹4.84 Cr -₹16.44 Lakh -₹2.7 Cr -₹1.97 Cr ₹12.25 Lakh -₹2.57 Cr ₹1.7 Cr ₹1.04 Cr
EBITDA (computed) ₹3.53 Cr -₹30.05 Lakh -₹1.38 Cr -₹3.04 Cr ₹1.91 Cr -₹1.62 Cr ₹73.8 Lakh -₹13.08 Lakh
Basic EPS ₹2.44 ₹-0.61 ₹-1.46 ₹-2.80 ₹1.38 ₹-1.64 ₹0.25 ₹-0.45
Diluted EPS ₹2.44 ₹-0.61 ₹-1.46 ₹-2.80 ₹1.38 ₹-1.64 ₹0.25 ₹-0.45
Latest 8 quarters shown.
Segment · Q4 FY26 (latest quarter) Revenue Result (PBIT) Assets Liabilities
Pharma Devision ₹2.92 Cr ₹3.35 Cr ₹48.12 Cr ₹3.22 Cr
Real Estate Devision ₹53.35 Lakh -₹32.73 Lakh ₹67.34 Cr ₹62.82 Lakh
Other ₹0 ₹0 ₹0 ₹0
Segment · FY 2026 (annual) Revenue Result (PBIT) Assets Liabilities
Pharma Devision ₹10.14 Cr -₹2.89 Cr - -
Real Estate Devision ₹2.31 Cr -₹12.46 Lakh - -
Other ₹0 ₹0 - -
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹2.31 Cr ₹2.42 Cr ₹7.17 Cr ₹10.14 Lakh ₹0 ₹0 ₹11.47 Cr ₹22.49 Cr
Other Income ₹57.65 Lakh ₹56.25 Lakh ₹14.72 Lakh ₹64.46 Lakh ₹60.74 Lakh ₹0 ₹55.15 Lakh ₹26.63 Lakh
Total Income ₹2.88 Cr ₹2.98 Cr ₹7.31 Cr ₹74.6 Lakh ₹60.74 Lakh ₹0 ₹12.03 Cr ₹22.76 Cr
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹5.41 Cr ₹10.5 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹15.26 Lakh
Changes in Inventories ₹33,000 ₹45,000 ₹1.2 Lakh ₹0 ₹0 ₹0 ₹4.53 Cr -₹51.81 Lakh
Employee Benefit Expense ₹1.85 Cr ₹1.81 Cr ₹82.88 Lakh ₹23.27 Lakh ₹45.13 Lakh ₹0 ₹5.88 Cr ₹5.19 Cr
Finance Costs ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹86,000 ₹1.36 Lakh
Depreciation & Amortisation ₹18.58 Lakh ₹16.01 Lakh ₹16.01 Lakh ₹9.23 Lakh ₹9.23 Lakh ₹0 ₹35.54 Lakh ₹35.02 Lakh
Other Expenses ₹96.47 Lakh ₹71.9 Lakh ₹1.48 Cr ₹16.53 Lakh ₹12.46 Lakh ₹0 ₹4.16 Cr ₹6.36 Cr
Total Expenses ₹3.01 Cr ₹2.69 Cr ₹2.49 Cr ₹49.03 Lakh ₹66.82 Lakh ₹0 ₹20.34 Cr ₹22.05 Cr
Profit Before Exceptional Items & Tax -₹12.46 Lakh ₹28.5 Lakh ₹4.83 Cr ₹25.57 Lakh -₹6.08 Lakh ₹0 -₹8.32 Cr ₹70.76 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹12.46 Lakh ₹28.5 Lakh ₹4.83 Cr ₹25.57 Lakh -₹6.08 Lakh ₹0 -₹8.32 Cr ₹70.76 Lakh
Total Tax Expense ₹1.41 Lakh -₹27.01 Lakh ₹93.91 Lakh -₹14,000 ₹1.44 Lakh -₹51,000 ₹84,000 ₹11.65 Lakh
Net Profit -₹13.87 Lakh ₹55.51 Lakh ₹3.89 Cr ₹14.64 Lakh -₹3.8 Lakh -₹11.08 Lakh -₹8.33 Cr ₹59.11 Lakh
Other Comprehensive Income -₹49.34 Lakh ₹29.95 Lakh ₹1.49 Cr -₹32.7 Lakh ₹35.69 Lakh ₹1.23 Cr ₹66.41 Lakh ₹0
Total Comprehensive Income -₹63.21 Lakh ₹85.46 Lakh ₹5.38 Cr -₹18.06 Lakh ₹31.89 Lakh ₹1.12 Cr -₹7.66 Cr ₹59.11 Lakh
EBITDA (computed) ₹6.12 Lakh ₹44.51 Lakh ₹4.99 Cr ₹34.8 Lakh ₹3.15 Lakh ₹0 -₹7.95 Cr ₹1.07 Cr
Basic EPS ₹-0.11 ₹0.45 ₹3.12 ₹0.21 ₹-0.06 ₹0.99 ₹-6.14 ₹0.47
Diluted EPS ₹-0.11 ₹0.45 ₹3.12 ₹0.21 ₹-0.06 ₹0.99 ₹-6.14 ₹0.47
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹67.34 Cr ₹68.03 Cr ₹68.09 Cr ₹61.63 Cr ₹61.81 Cr ₹62.64 Cr ₹61.55 Cr ₹73.78 Cr
Non-current Assets ₹46.2 Cr ₹46.13 Cr ₹46.22 Cr ₹46.42 Cr ₹46.73 Cr ₹47.4 Cr ₹49.15 Cr ₹51.31 Cr
Current Assets ₹21.14 Cr ₹21.9 Cr ₹21.88 Cr ₹15.2 Cr ₹15.07 Cr ₹15.23 Cr ₹12.4 Cr ₹22.47 Cr
Property, Plant & Equipment ₹2.23 Cr ₹2.1 Cr ₹2.26 Cr ₹2.46 Cr ₹2.78 Cr ₹3.26 Cr ₹3.63 Cr ₹3.91 Cr
Inventories ₹2.38 Lakh ₹2.71 Lakh ₹3.16 Lakh ₹0 ₹0 ₹4.94 Lakh ₹53.26 Lakh ₹6.95 Cr
Trade Receivables ₹2.95 Cr ₹3.66 Cr ₹4.65 Cr ₹2.24 Cr ₹2.24 Cr ₹2.41 Cr ₹2.66 Cr ₹6.25 Cr
Cash & Equivalents ₹70,000 ₹5.24 Lakh ₹4.54 Lakh ₹4.05 Lakh ₹9,000 ₹20,000 ₹74.52 Lakh ₹2.13 Cr
Equity (Net Worth) ₹66.71 Cr ₹67.34 Cr ₹66.49 Cr ₹61.11 Cr ₹61.29 Cr ₹60.97 Cr ₹59.85 Cr ₹67.51 Cr
Equity Share Capital ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr ₹12.47 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh
Borrowings (Current) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹5.8 Lakh
Total Debt (computed) ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6.35 Lakh ₹12.15 Lakh
Current Liabilities ₹22.81 Lakh ₹26.82 Lakh ₹1.17 Cr ₹7.81 Lakh ₹7.62 Lakh ₹1.11 Cr ₹1.03 Cr ₹4.51 Cr
Total Liabilities ₹62.82 Lakh ₹68.27 Lakh ₹1.6 Cr ₹51.79 Lakh ₹51.75 Lakh ₹1.67 Cr ₹1.71 Cr ₹6.27 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹46.99 Lakh ₹1.85 Cr ₹3.09 Cr -₹2.6 Cr -₹95.08 Lakh
Investing Cash Flow ₹42.45 Lakh -₹1.85 Cr -₹3.09 Cr ₹1.85 Cr ₹1.01 Cr
Financing Cash Flow ₹0 ₹0 ₹0 ₹0 ₹0
Capital Expenditure ₹24.7 Lakh ₹7.12 Lakh ₹0 ₹0 ₹0
Free Cash Flow (computed) -₹71.69 Lakh ₹1.78 Cr ₹3.09 Cr -₹2.6 Cr -₹95.08 Lakh
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹4.54 Lakh ₹70,000 ₹49,000 -₹74.63 Lakh ₹5.89 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹53.35 Lakh ₹77.28 Lakh ₹99.96 Lakh ₹0 ₹89.08 Lakh ₹26.04 Lakh ₹97.52 Lakh ₹29.02 Lakh
Other Income ₹8.02 Lakh ₹17.32 Lakh ₹97,000 ₹31.33 Lakh ₹26.91 Lakh ₹8.96 Lakh ₹9.66 Lakh ₹10.72 Lakh
Total Income ₹61.37 Lakh ₹94.6 Lakh ₹1.01 Cr ₹31.33 Lakh ₹1.16 Cr ₹35 Lakh ₹1.07 Cr ₹39.74 Lakh
Cost of Materials Consumed ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹8,000 ₹10,000 ₹15,000 ₹0 ₹17,000 ₹6,000 ₹17,000 ₹6,000
Employee Benefit Expense ₹47.02 Lakh ₹46.73 Lakh ₹45.9 Lakh ₹45.67 Lakh ₹44.91 Lakh ₹45.52 Lakh ₹45.38 Lakh ₹45.23 Lakh
Finance Costs ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Depreciation & Amortisation ₹6.58 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh ₹4 Lakh
Other Expenses ₹40.42 Lakh ₹12.42 Lakh ₹22.23 Lakh ₹21.41 Lakh ₹23.31 Lakh ₹11.89 Lakh ₹13.09 Lakh ₹23.62 Lakh
Total Expenses ₹94.1 Lakh ₹63.25 Lakh ₹72.28 Lakh ₹71.08 Lakh ₹72.39 Lakh ₹61.47 Lakh ₹62.64 Lakh ₹72.91 Lakh
Profit Before Exceptional Items & Tax -₹32.73 Lakh ₹31.35 Lakh ₹28.65 Lakh -₹39.75 Lakh ₹43.6 Lakh -₹26.47 Lakh ₹44.54 Lakh -₹33.17 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax -₹32.73 Lakh ₹31.35 Lakh ₹28.65 Lakh -₹39.75 Lakh ₹43.6 Lakh -₹26.47 Lakh ₹44.54 Lakh -₹33.17 Lakh
Total Tax Expense -₹1.44 Lakh ₹2.85 Lakh ₹0 ₹0 -₹27.01 Lakh ₹0 ₹0 ₹0
Net Profit -₹31.29 Lakh ₹28.5 Lakh ₹28.65 Lakh -₹39.75 Lakh ₹70.61 Lakh -₹26.47 Lakh ₹44.54 Lakh -₹33.17 Lakh
Other Comprehensive Income -₹1.14 Cr ₹22.62 Lakh -₹11.83 Lakh ₹54.25 Lakh -₹25.36 Lakh -₹38.46 Lakh ₹47.32 Lakh ₹46.46 Lakh
Total Comprehensive Income -₹1.46 Cr ₹51.12 Lakh ₹16.82 Lakh ₹14.5 Lakh ₹45.25 Lakh -₹64.93 Lakh ₹91.86 Lakh ₹13.29 Lakh
EBITDA (computed) -₹26.15 Lakh ₹35.35 Lakh ₹32.65 Lakh -₹35.75 Lakh ₹47.6 Lakh -₹22.47 Lakh ₹48.54 Lakh -₹29.17 Lakh
Basic EPS ₹-0.25 ₹0.23 ₹0.23 ₹-0.32 ₹0.57 ₹-0.21 ₹0.36 ₹-0.27
Diluted EPS ₹-0.25 ₹0.23 ₹0.23 ₹-0.32 ₹0.57 ₹-0.21 ₹0.36 ₹-0.27
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Medicaps Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Medicaps Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 51.36%, domestic institutional investors hold 0.02%, retail and other public shareholders hold 48.61% of Medicaps Limited. The company had 10,349 shareholders on record.

Promoters: 51.36%DII (Domestic Institutional): 0.02%Retail & Others: 48.61%
Mar 2026
QUARTER
51.36% Promoters
0.02% DII (Domestic Institutional)
48.61% Retail & Others
Promoter holding - history
Now 51.36% · Mar 2026High 51.36% · Mar 2026Low 50.13% · Jun 2023
49%50%51%52%53%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 50.13%Sep 2023: 50.13%Dec 2023: 50.13%Mar 2024: 50.13%Jun 2024: 50.13%Sep 2024: 50.43%Dec 2024: 50.62%Mar 2025: 50.77%Jun 2025: 50.77%Sep 2025: 50.77%Dec 2025: 50.76%Mar 2026: 51.36%50.13%51.36%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters51.36%50.76%50.77%50.77%50.77%50.62%
Public48.64%49.24%49.23%49.23%49.23%49.38%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters51.36%50.77%50.13%
Public48.64%49.23%49.87%
Promoter change (YoY, %pts)+0.59+0.64-

Group Structure of Medicaps Limited

Medicaps Limited has 1 subsidiary company. This group structure data is as of FY 2022. The corporate group structure reflects Medicaps Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Medgel Private Limited U24239MP2007PTC019204 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Medicaps Limited

Open charges
₹20 Lakh
Satisfied charges
₹2.22 Cr
Breakdown by lending institutions
Bank of Baroda₹0.20 Cr
Latest charge details
DateLenderAmountStatus
24 Mar 1992 Bank of Baroda ₹3 Lakh Open
05 Oct 1990 Bank of Baroda ₹10 Lakh Open
24 Jul 1986 Bank of Baroda ₹7 Lakh Open
03 Mar 2018 Axis Bank Limited ₹17.46 Lakh Satisfied
22 Jan 1996 I.D.B.I. Bank Ltd. ₹1.15 Cr Satisfied

Total charge records: 6 View all charges

Employees and EPFO Compliance at Medicaps Limited

Medicaps Limited has a workforce of 2 employees as of Apr 05, 2024.

Employee count
2
Active EPFO establishments
1
Employee growth
-98.25%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Medicaps Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Medicaps Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Medicaps Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Medicaps Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Medicaps Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Medicaps Limited

MSME Payment Delays by Medicaps Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Medicaps Limited

Subsidiaries & Group Companies of Medicaps Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Medicaps Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Medicaps Limited

MCA Filings & Documents of Medicaps Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Medicaps Limited

Activity
18 Sep 2025
Medicaps Limited last Annual general meeting of members was held on 18 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Medicaps Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior.
Directors
11 Aug 2023
Gajendra Singh was appointed as a Director on 11 Aug 2023 & has been associated with this company since 2 years 10 months.
Directors
10 Feb 2022
Abhishek Kumar was appointed as a Company Secretary on 10 Feb 2022 & has been associated with this company since 4 years 4 months.
Directors
10 Feb 2022
Abhishek Jain was appointed as a Company Secretary on 10 Feb 2022 & has been associated with this company since 4 years 4 months.
Charges
23 Mar 2021
A charge registered on 03 Mar 2018 via Charge ID 100193845 with Axis Bank Limited was fully satisfied on 23 Mar 2021.

Frequently Asked Questions about Medicaps Limited

Medicaps Limited is an active public limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 06 August 1983 (43+ years old) and is registered under CIN L70100MP1983PLC002231. Listed on BSE: 523144. The company has 2 employees.

Medicaps Limited reported revenue of ₹28.21 Cr for FY 2025 (up 1.00% YoY).

The current directors of Medicaps Limited are:

The primary industry of Medicaps Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Medicaps Limited is listed on BSE with code 523144.

Yes, Medicaps Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available